Correction: An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes

Correction to: Endocrine (2023) 82:215–225

https://doi.org/10.1007/s12020-023-03473-w

In this article, the mean absolute relative difference (MARD) for the rtCGM/Glunovo i3/Flash device in Table1, column MARD, was initially reported as 9.3%. The value has been rectified to 10.3% in this erratum.

Table S1. Characteristics of currently available CGM devices

CGM type/sensor	Reading period/sensor lifetime/transmitter lifetime	Calibrations (n/day)	Smartphone compatibility/ CSII integrated (SAP/AP)	MARD	Insertion site	% 15/15 mg/dl overalle	% 20/20 mg/dl overallf	Data management	Adjunctive use/non adjunctive use	Use in pregnancyi	Intended populations
rtCGM/Dexcom G6	10 days/10 days/ 3 months	0	Yes/Yes	9%	Abdomen, arm, upper gluteusd	83.3%	93.9%	Clarity/Diasend/ Glooko	Non adjunctive use	Indicated	2 years and older
rtCGM/Dexcom G7	10 days/10 daysb (+12 h tolerance)	0	Yes/Yes	8.2%	Abdomen, arm, upper gluteusd	89.6%g	95.3%g	Clarity/ Glooko	Non adjunctive use	Indicated	2 years and older
rtCGM/TouchCare A7+	10 days /10 days/ 12 months	1	Yes/Yes	9%	Abdomen, upper gluteus	NA	NA	EasyView Pro	Non adjunctive use	Not specified	2 years and older
rtCGM/Eversense E3a	180 days/180 days/12 months	2/1c	Yes/No	8.5%	Upper arm	85.6%	92.9%	Eversense DMS	Non adjunctive use	Not indicated	18 years and older
rtCGM/GlucoMen Day	14 days/14 days/ 5 years	1	Yes/No	9.6%	Abdomen	NA	NA	Glucolog/Diasend/ Glooko	Non adjunctive use	Indicated	6 years and older
rtCGM/Glunovo i3/Flash	14 days/14 days/ 3 years	0	Yes/No	10.3%	Abdomen	79.31%	89.71%	IrisHealthCare	Adjunctive use	Indicated	2 years and older
rtCGM/Guardian sensor 3	7 days/7 days/ 12 months	2	No/Yes	9.1%	Abdomen, arm	78.8%	88.2%	Carelink	Adjunctive useh	Not specified	2 years and older
rtCGM/Guardian sensor 4	7 days/7 days/ 12 months	0	No/Yes	10.6%	Abdomen, arm, upper gluteusd	NA	NA	Carelink	Non adjunctive use	Not specified	2 years and older
iCGM/Freestyle libre	14 days/14 daysb	0	Yes/No	9.2%	Arm	NA	NA	Libreview	Non adjunctive use	Indicated	4 and older
iCGM/Freestyle libre 2	14 days/14 daysb	0	Yes/No	9.2%	Arm	86.3%	93.2%	Libreview	Non adjunctive use	Indicated	4 and older
rtCGM/Freestyle libre 3	14 days/14 daysb	0	Yes/No	7.9%	Arm	89.1%	94.7%	Libreview	Non adjunctive use	Indicated	4 and older

1. AP artificial pancreas, CGM continuous glucose monitoring, CSII continuous subcutaneous insulin infusion, iCGM intermittently scanned glucose monitoring, MARD mean absolute relative difference, rtCGM real-time continuous glucose monitoring, SAP sensor augmented pump.
2. ^aImplantable sensor.
3. ^bThe sensor and the transmitter work as one unit.
4. ^cEversense E3 requires 2 calibration/day for the first 21 days of use and after 1 calibration/day.
5. ^dUpper gluteus refers to pediatric use between 2 and 17 years of age.
6. ^eOverall agreement rate between paired sensor–reference values within ±15%/15%.
7. ^fOverall agreement rate between paired sensor–reference values within ±20%/20%.
8. ^gOverall agreement rate for arm-placed sensors.
9. ^hApproved for non adjunctive use only in conjunction with MiniMed 780G.
10. ⁱUse in pregnancy according to the technical sheet.

The original article has been corrected.